Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)

• Stage I-III female breast cancer (including inflammatory and newly diagnosed or locally recurrent breast cancer) but not metastatic breast cancer being treated with curative intent

• \> 18 years old

• Scheduled to receive chemotherapy and/or estrogen antagonist aromatase inhibitors (anastrozole \[Arimidex\], letrozole \[Femara\], exemestane \[Aromasin\]).

• Able to hold breath for 10 seconds

• ECOG performance status 0 -2

• Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting

• Able to exercise on a treadmill or stationary cycle

• Participants in other ongoing clinical trials are eligible for this study

• Healthy female without known coronary artery disease \> 18 years old

• Able to hold breath 10 seconds

• ECOG performance status = 0 or 1

• Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting

• Able to exercise on a treadmill or stationary cycle

• No personal history of cancer other than superficial skin cancers

• Has never received chemotherapy, radiation therapy, immunotherapy, or had breast cancer related surgery

• If previously measured, LVEF ≥ 50%